Dupilumab efficacy in children with uncontrolled type 2 asthma with baseline high/medium ICS dose

Conclusion: DPL demonstrated clinical efficacy in both ICS groups, with reductions in AER in both groups, and significant and numeric improvements in ppFEV1 in the med- and high-dose ICS groups, respectively.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Maspero, J. F., Antila, M. A., Jain, N., Deschildre, A., Bacharier, L. B., Altincatal, A., Laws, E., Akinlade, B., Siddiqui, S., Jacob-Nara, J. A., Deniz, Y., Rowe, P. J., Lederer, D. J., Hardin, M. Tags: 07.02 - Paediatric asthma and allergy Source Type: research